9 results for "Quality "
EAQ162CD: Financial Burden Assessment in Patients with Stage I-III Colon or Rectal Cancer Undergoing Treatment
This research trial studies the financial burden in patients with Stage I-III Colon or Rectal Cancer who are undergoing treatment. Collecting data from patients about their cost and quality of life may help doctors to better understand the impact of cancer treatment on a patient’s employment and finances.
This study looks at the risks and benefits of active surveillance (AS) compared to guideline concordant care (GCC) in the setting of a pragmatic prospective randomized trial for low risk DCIS. Our overarching hypothesis is that management of low-risk Ductal Carcinoma in Situ (DCIS) using an AS approach does not yield inferior cancer or quality of life outcomes compared to GCC.
The purpose of this study is to describe patterns of care in CRPC patients, as well as health-related quality of life (HRQoL) outcomes associated with CRPC and its management.
This study will also describe factors influencing treatment decisions including reason(s) for treatment choices and triggers for treatment changes for CRPC as well as describe clinical outcomes based on patient characteristics.
ALTE05N1: Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
This clinical trial keeps track of and collects follow-up information from patients who are currently enrolled on or have participated in a Children's Oncology Group study. Developing a way to keep track of patients who have participated in Children's Oncology Group studies may allow doctors learn more about the long-term effects of cancer treatment and help them reduce problems related to treatment and improve patient quality of life.
The purpose of this study is to determine if xylitol sinonasal irrigation, in combination with topical steroid/antibiotics, will disrupt the biofilms and improve disease control of CRS patients with chronically draining sinuses. Topical xylitol could potentially decrease CRS symptoms, leading to improvements in patient quality of life. This decrease could potentially lead to fewer visits to primary care physicians/otolaryngologists. These could lead to less antibiotics, radiographs being obtained and unnecessary surgical procedures being performed, all of which could potentially reduce the burden of medical expenditure in the treatment of this disease.
GLOW: Zolbetuximab (IMAB362) + CAPOX VS. Placebo + CAPOX as 1st-line Treatment for CLDN18.2 (+), HER2 (-) Gastric or GEJ Cancer
The purpose of this study is to evaluate the efficacy of Zolbetuximab plus Capecitabine and Oxaliplatin (CAPOX) compared with placebo plus CAPOX (as first-line treatment) for Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma as measured by Progression Free Survival (PFS). This study will also evaluate efficacy, safety and tolerability of Zolbetuximab, as well as its effects on quality of life. Pharmacokinetics (PK) of Zolbetuximab and the immunogenicity profile of Zolbetuximab will be evaluated as well.
This randomized phase III trial studies how well cisplatin or carboplatin (platinum based chemotherapy) works compared to observation in treating patients with remaining (residual) basal-like triple-negative breast cancer following chemotherapy after surgery (neoadjuvant). Drugs used in chemotherapy, such as cisplatin and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether cisplatin or carboplatin is more effective than observation in treating patients with residual triple negative basal-like breast cancer.
This study will look at patients with a complaint of Posterior nasal drip (PND) who undergo sinonasal surgery and will attempt to link posterior inferior turbinate hypertrophy (PITH) to PND. All patients will have a preoperative nasal endoscopy in clinic to assess for PITH. All patients will complete preoperative quality of life forms, previously validated Sino-nasal Outcome Test (SNOT 22) and Nasal Obstruction and Septoplasty Effectiveness (NOSE) forms. Patients will undergo a computed tomography (CT) scan as deemed appropriate by Dr. McCoul. Patients will then be electively enrolled for surgery. All the preceding steps will occur in the course of routine clinical care and are unchanged by study participation. While under general anesthesia, small biopsies of the posterior inferior turbinate, the anterior head of the inferior turbinate (at the incision site for routine submucosal resection of the inferior turbinate (SMRT), and the anterior nasal septum will be obtained and sent to pathology. The pathology department will then evaluate the biopsies for markers of inflammation.